Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

BLACKSTONE is buying a company that helps drugmakers run clinical trials in Japan, adding to growing interest from private ...

Mitsubishi Tanabe Pharma is being sold to Bain Capital for about $3.3 billion. Eisai expects a Leqembi "expansion phase" on the horizon. And more. 1. Astellas shifts investment focus to later ...

Global private equity and venture capital deal value reached $37.93 billion in February, up 26.6% from January, according to ...

Blackstone Inc. is buying a company that helps drugmakers run clinical trials in Japan, adding to growing interest from ...

Last month, Ropes & Gray, Morrison & Foerster and Big Four Japanese firm Mori Hamada were seen advising in Boston-based Bain ...

Private equity giant Blackstone is going big on Japan, acquiring a majority stake in the country’s leading contract research ...

Bain Capital said it will buy Mitsubishi Chemical’s pharma business for $3.37 billion. Sanofi and CD&R signed an Opella share purchase agreement. Biogen partnered with Stoke Therapeutics on a drug for ...